BOSTON, Sept. 30, 2024 -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today...
Researchers, university tech transfer offices, pharmaceutical companies, and disease-focused philanthropic organizations often face a challenge in translating academic research projects into viable licensing candidates or start-up companies. Pappas Translational Medicine works hands-on with our partners to help identify, catalyze and manage those projects that have the best chance to become market-ready.
We target life science technologies and platforms with high potential to reach private-sector transaction-enabling milestones—with the goal of expanding the pipeline of high quality translational medicine programs.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.